晚期高级别浆液性卵巢癌70岁及以上患者应进行同源重组缺陷检测
基于VELIA三期试验数据,比较70岁以下与70岁及以上晚期高级别浆液性卵巢癌患者的同源重组缺陷(HRD)及BRCA1/2致病变异频率;排除胚系BRCA贡献后两组HRD频率相似(35% vs 31%),体细胞BRCA变异率亦相似(8% vs 10%),支持老年患者诊断时进行HRD和BRCA检测。
要点
- 1140例参与者中21%为70岁及以上。
- 排除胚系BRCA贡献后,HRD频率在<70岁与≥70岁组相似(35% vs 31%)。
- 体细胞BRCA致病变异率两组相似(8% vs 10%),支持老年患者诊断时检测。
核心结论
- 当排除胚系BRCA的贡献后,<70岁与≥70岁参与者的HRD频率相似(35% vs 31%),体细胞BRCA致病变异率也相似(8% vs 10%),鉴于治疗意义,强调老年晚期HGSC患者诊断时进行HRD和BRCA检测的重要性。
研究设计与样本
- VELIA三期试验中,比较<70岁与≥70岁参与者的HRD及BRCA1/2致病变异频率;诊断时用Myriad myChoice® CDx检测HRD和体细胞BRCA1/2致病变异,用Myriad BRACAnalysis CDx®检测胚系BRCA1/2致病变异;HRD定义为存在BRCA致病变异或基因组不稳定性评分(GIS)达到阈值(分别分析GIS ≥ 33和GIS ≥ 42)。
主要发现
- 1140例参与者中21%为≥70岁;总体中26%(n=298)为BRCA1/2致病变异且HRD,29%(n=329)为HRD/BRCA野生型,33%(n=372)为非HRD,12% HR状态未知(n=141)。
- GIS ≥ 42时,<70岁参与者HRD率为59%(n=476/802),≥70岁为40%(n=78/197),p < 0.001。
- GIS ≥ 33时,<70岁HRD率为66%,≥70岁为48%,p < 0.001。
- 胚系BRCA致病变异在<70岁为24%,≥70岁为8%(p < 0.001);体细胞BRCA致病变异为8% vs 10%(p = 0.2559);非胚系BRCA导致的HRD(GIS ≥ 42)为35% vs 31%(p = 0.36)。
关键数值与推荐
- HRD定义为存在BRCA致病变异或GIS达到阈值(GIS ≥ 33和GIS ≥ 42分别分析)。
临床怎么用
- 作者强调鉴于治疗意义,老年晚期HGSC患者诊断时应进行HRD和BRCA检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Due to limited data on homologous recombination deficiency (HRD) in older patients (≥ 70 years) with advanced stage high grade serous ovarian cancer (HGSC), we aimed to determine the rates of HRD at diagnosis in this age group. METHODS: From the Phase 3 trial VELIA the frequency of HRD and BRCA1/2 pathogenic variants (PVs) was compared between younger (< 70 years) and older participants. HRD and somatic(s) BRCA1/2 pathogenic variants (PVs) were determined at diagnosis using Myriad myChoice® CDx and germline(g) BRCA1/2 PVs using Myriad BRACAnalysis CDx®. HRD was defined if a BRCA PV was present, or the genomic instability score (GIS) met threshold (GIS ≥ 33 & ≥ 42 analyzed). RESULTS: Of 1140 participants, 21% were ≥ 70 years. In total, 26% (n = 298) had a BRCA1/2 PV and HRD, 29% (n = 329) were HRD/BRCA wild-type, 33% (n = 372) non-HRD, and 12% HR-status unknown (n = 141). HRD rates were higher in younger participants, 59% (n = 476/802), compared to 40% (n = 78/197) of older participants (GIS ≥ 42) [p < 0.001]; similar rates demonstrated with GIS ≥ 33, 66% vs 48% [p < 0.001]. gBRCA PVs observed in 24% younger vs 8% of older participants (p < 0.001); sBRCA in 8% vs 10% (p = 0.2559), and HRD (GIS ≥ 42) not due to gBRCA was 35% vs 31% (p = 0.36). CONCLUSIONS: HRD frequency was similar in participants aged < 70 and ≥ 70 years (35% vs 31%) when the contribution of gBRCA was excluded; rates of sBRCA PVs were also similar (8% v 10%), thus underscoring the importance of HRD and BRCA testing at diagnosis in older patients with advanced HGSC given the therapeutic implications.
引用
- Pitiyarachchi O, Ansell PJ, Coleman RL, et al. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over. Gynecol Oncol. 2024. PMID: 38821039. doi:10.1016/j.ygyno.2024.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。